Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cougar Biotechnology
Fortress Biotech: A Drug Financing Experiment Expands
Fortress Biotech has established nine subsidiary companies since 2013, each financed differently and each focused on an area of unmet need. Fortress CEO and longtime life sciences investor Lindsay Rosenwald lays out his ambitious plans for the future.
J&J’s Oncology Strategy: Aim For Next-Gen Immuno-Oncology, More M&A
Johnson & Johnson has built a strong oncology business by making smart partnering plays. Now the company is looking to write a new chapter, building on its single-asset successes with a portfolio of new cancer drugs developed both internally and through more M&A.
Puma triples on neratinib adjuvant breast cancer data
Puma Biotechnology's stock tripled in after-hours trading on 22 July after the company said it would seek regulatory approval based on Phase III results for its tyrosine kinase inhibitor neratinib in a Phase III clinical trial for the extended adjuvant treatment of breast cancer.
BioNotebook: Puma CEO sees sale as option, Tesaro drops, Can-Fite gains on study results
'Tis the season to dump good and bad news just before the holidays. Despite the upbeat headline in the company's press release, Tesaro reported mixed results for a late-stage experimental drug. Can-Fite BioPharma had better news. And Puma Biotechnology's CEO, a man with a love of big cat names, vows to do what's right for his shareholders.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.